Inato

Missed our #SCOPEsummit panel? We’ve got you covered. Today we’re recapping our conversation with Sanofi's Nadir AMMOUR and Novum Research's Jovani Rivera on the patient recruitment bottleneck and how AI can help sites and sponsors tackle this challenge. Check out key panel takeaways and learn more about our collaboration to reduce site burden and accelerate patient identification, screening, and enrollment: https://lnkd.in/eA-jiCNV

🚀 Celebrating Innovation: Synapse Innovator's Showcase at Boehringer Ingelheim HQ. We've just concluded an inspiring Innovator's Showcase, marking the successful completion of Boehringer Ingelheim's innovation program, Synapse's 7th Wave, which BI X have conducted with the support of Vertical! For the final event we brought together innovative startups, industry experts, and healthcare pioneers to shape the future of digital health. Key highlights: ▪️ moka.care demonstrated remarkable success in digital health transformation, showcasing how Synapse enables meaningful collaboration between startups and Boehringer Ingelheim business owners / Arthur Dupont, Estelle P. ▪️Inato presented an innovative pilot focused on enhancing diversity in clinical trials and optimizing site selection / Marcy Kravet, Geoff Ainslie, Elena (Ershova) Ustiugova, Andrew Sutton. ▪️Engaging panel discussions explored strategies for involving smaller sites and diverse populations in clinical trials. ▪️Productive roundtable sessions connected Boehringer Ingelheim experts with Synapse alumni and project owners, validating future innovation topics. Learn more about Synapse: https://lnkd.in/dTBg5zA8 #Synapse #BIX #Innovation #Healthcare #StartupCollaboration #OpenInnovation #FutureOfHealth #DigitalHealth

“There’s a lot of buzz about AI in the pharmaceutical industry, but it’s largely been focused on discovery. I understand the promise and allure of this: it’s exciting, it’s linked directly to the science, it could lead to the next big medical breakthrough. Yet…The biggest barrier to bringing new drugs to market isn’t discovery; it’s clinical trials.” Our co-founder and Chief Strategy Officer Liz Beatty shares her thoughts on the year ahead in clinical trials–from AI’s growing influence to community site engagement–in pharmaphorum: https://lnkd.in/eM-Hmg5N

Finding and screening patients for trials used to be a time-consuming, burdensome process for the staff at Pantheon Clinical Research. Now, they use Inato. Learn more about how this site worked with Inato to transform patient identification and pre-screening at scale, empower site staff, and accelerate trial timelines 🚀 https://lnkd.in/dvjf8SYU P.S. - any U.S. site can try patient pre-screening for free today: https://lnkd.in/dVJfZrY2 

Tune in Monday for this SOS Save Our Sites roundtable featuring our co-founder and Chief Strategy Officer, Liz Beatty. Liz will sit down with the SOS co-founders to discuss how Inato reduces burden for 5,000+ sites, including insights into our new AI capabilities that enable sites to identify and pre-screen patients in minutes instead of hours. https://lnkd.in/egbR3XWC

We’re #SCOPEsummit ready! Swing by booth 508 to chat with the Inato team, and don’t miss our panel at 4:25pm with Sanofi and Novum Clinical Research exploring how recent advances in AI unlock the ability to find and engage the right patients at scale.

Excited to speak on this #SCOPEsummit panel on reimagining clinical trials alongside leaders from Novartis, Faro Health, IgniteData, and Yseop. AI in drug discovery is the talk of the town, but the real bottleneck in bringing new drugs to market is the clinical trial process. There are significant, often-overlooked opportunities for AI to accelerate and enhance trials, and I’m looking forward to discussing some of the possibilities on February 5th. If you can’t make this session, I hope to catch you earlier in the week. Drop by booth 508 to chat with the Inato team or swing by Inato’s panel at 4:25pm on February 4th! 

Are you at #SCOPEsummit this week? Do you often need an afternoon pick-me-up? Are you interested in learning more about how #AI can accelerate patient identification, screening, and enrollment? If the answer is yes to all three, swing by to see the Inato team at booth 508! We’ll have a coffee cart on Tuesday afternoon (2:40pm) and a popcorn cart on Wednesday (1:45pm) to help you refuel for an afternoon of panels and mingling. And if pizza, apps, and drinks are more your style, it’s not too late to RSVP for our Tuesday night reception: https://lnkd.in/ebUNuJfq

📣 Calling all research sites: we just launched new capabilities to transform patient identification and pre-screening 📣 Inato patient pre-screening leverages AI to assess patient eligibility for all trials across a site’s portfolio–quickly, accurately, and at scale. Sites across the U.S. can use these capabilities for free to reduce patient pre-screening times from hours to minutes. Learn more about how Inato can help reduce site burden, streamline patient identification and pre-screening, and help accelerate enrollment: https://lnkd.in/e5epqWeF

Recruiting and enrolling the right patients is one of the biggest challenges in clinical trials. Recent advances in AI promise to fundamentally transform how sites and sponsors approach these processes.   Next week at #SCOPEsummit, we’re hosting a panel on AI’s potential to reshape patient identification and screening. Our co-founders Liz Beatty and Kourosh Davarpanah will sit down with Sanofi's Nadir AMMOUR and Novum Research's Jovani Rivera to discuss our collaboration to alleviate site burden and accelerate trial operations at scale. Don’t miss it!